4.3 Article

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy

Related references

Note: Only part of the references are listed.
Review Clinical Neurology

Red-flag symptom clusters in transthyretin familial amyloid polyneuropathy

Isabel Conceicao et al.

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2016)

Article Biochemistry & Molecular Biology

Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis

Yoshiki Sekijima et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2015)

Review Clinical Neurology

Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments

Yoshiki Sekijima

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)

Review Clinical Neurology

A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis

Marcia Waddington Cruz et al.

NEUROLOGY AND THERAPY (2015)

Review Pharmacology & Pharmacy

Tafamidis: A Review of Its Use in Familial Amyloid Polyneuropathy

Lesley J. Scott

DRUGS (2014)

Article Genetics & Heredity

Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations

Dorota M. Rowczenio et al.

HUMAN MUTATION (2014)

Article Clinical Neurology

Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy

Violaine Plante-Bordeneuve

JOURNAL OF NEUROLOGY (2014)

Article Medicine, General & Internal

Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial

John L. Berk et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

Review Genetics & Heredity

Guideline of transthyretin-related hereditary amyloidosis for clinicians

Yukio Ando et al.

ORPHANET JOURNAL OF RARE DISEASES (2013)

Article Clinical Neurology

Recent advances in the treatment of familial amyloid polyneuropathy

David Adams

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2013)